Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2572-2580 |
| Number of pages | 9 |
| Journal | Journal of Cellular Physiology |
| Volume | 233 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Keywords
- cancer patients
- contrast induced nephropathy
- low-osmolar/iso-osmolar contrast medium
- iodixanol
- iopromide
- contrast medium
- iodobenzoic acid derivative
- iohexol
- abdomen
- adult
- aged
- Article
- cancer patient
- clinical assessment
- contrast enhancement
- controlled study
- drug safety
- estimated glomerular filtration rate
- female
- human
- low risk patient
- major clinical study
- male
- multicenter study
- outcome assessment
- pelvis
- priority journal
- randomized controlled trial
- single blind procedure
- thorax
- x-ray computed tomography
- adolescent
- analogs and derivatives
- chemically induced
- clinical trial
- comparative study
- diagnostic imaging
- drug effects
- glomerulus filtration rate
- Italy
- kidney
- kidney disease
- middle aged
- neoplasm
- pathology
- pathophysiology
- patient safety
- predictive value
- risk factor
- time factor
- young adult
- Adolescent
- Adult
- Aged
- Contrast Media
- Female
- Glomerular Filtration Rate
- Humans
- Iohexol
- Kidney
- Kidney Diseases
- Male
- Middle Aged
- Neoplasms
- Patient Safety
- Predictive Value of Tests
- Risk Factors
- Time Factors
- Tomography, X-Ray Computed
- Triiodobenzoic Acids
- Young Adult
Cite this
Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. / Terrenato, I.; Sperati, F.; Musicco, F.; Pozzi, A.F.; di Turi, A.; Caterino, M.; de Lutio di Castelguidone, E.; Setola, S.V.; Bellomi, M.; Neumaier, C.E.; Conti, L.; Cigliana, G.; Merola, R.; Antenucci, A.; Orlandi, G.; Giordano, A.; Barba, M.; Canitano, S.
In: Journal of Cellular Physiology, Vol. 233, No. 3, 2018, p. 2572-2580.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial
AU - Terrenato, I.
AU - Sperati, F.
AU - Musicco, F.
AU - Pozzi, A.F.
AU - di Turi, A.
AU - Caterino, M.
AU - de Lutio di Castelguidone, E.
AU - Setola, S.V.
AU - Bellomi, M.
AU - Neumaier, C.E.
AU - Conti, L.
AU - Cigliana, G.
AU - Merola, R.
AU - Antenucci, A.
AU - Orlandi, G.
AU - Giordano, A.
AU - Barba, M.
AU - Canitano, S.
N1 - Cited By :1 Export Date: 5 February 2019 CODEN: JCLLA Correspondence Address: Barba, M.; Scientific Direction, Regina Elena National Cancer InstituteItaly; email: maddalena.barba@gmail.com Chemicals/CAS: iodixanol, 92339-11-2; iopromide, 73334-07-3; iohexol, 66108-95-0; Contrast Media; iodixanol; Iohexol; iopromide; Triiodobenzoic Acids Tradenames: ultravist, Schering; visipaque, GE Healthcare Manufacturers: GE Healthcare; Schering
PY - 2018
Y1 - 2018
N2 - To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms. © 2017 Wiley Periodicals, Inc.
AB - To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms. © 2017 Wiley Periodicals, Inc.
KW - cancer patients
KW - contrast induced nephropathy
KW - low-osmolar/iso-osmolar contrast medium
KW - iodixanol
KW - iopromide
KW - contrast medium
KW - iodobenzoic acid derivative
KW - iohexol
KW - abdomen
KW - adult
KW - aged
KW - Article
KW - cancer patient
KW - clinical assessment
KW - contrast enhancement
KW - controlled study
KW - drug safety
KW - estimated glomerular filtration rate
KW - female
KW - human
KW - low risk patient
KW - major clinical study
KW - male
KW - multicenter study
KW - outcome assessment
KW - pelvis
KW - priority journal
KW - randomized controlled trial
KW - single blind procedure
KW - thorax
KW - x-ray computed tomography
KW - adolescent
KW - analogs and derivatives
KW - chemically induced
KW - clinical trial
KW - comparative study
KW - diagnostic imaging
KW - drug effects
KW - glomerulus filtration rate
KW - Italy
KW - kidney
KW - kidney disease
KW - middle aged
KW - neoplasm
KW - pathology
KW - pathophysiology
KW - patient safety
KW - predictive value
KW - risk factor
KW - time factor
KW - young adult
KW - Adolescent
KW - Adult
KW - Aged
KW - Contrast Media
KW - Female
KW - Glomerular Filtration Rate
KW - Humans
KW - Iohexol
KW - Kidney
KW - Kidney Diseases
KW - Male
KW - Middle Aged
KW - Neoplasms
KW - Patient Safety
KW - Predictive Value of Tests
KW - Risk Factors
KW - Time Factors
KW - Tomography, X-Ray Computed
KW - Triiodobenzoic Acids
KW - Young Adult
U2 - 10.1002/jcp.26132
DO - 10.1002/jcp.26132
M3 - Article
VL - 233
SP - 2572
EP - 2580
JO - Journal of Cellular Physiology
JF - Journal of Cellular Physiology
SN - 1097-4652
IS - 3
ER -